Background {#Sec1}
==========

Advances in the management of RA have motivated an increasing interest in the early detection of the patients to ensure they obtain all the treatment benefits \[[@CR1]\]. Accordingly, the classification criteria for RA were modified in 2010 by the ACR and the EULAR to include patients in the early phases of the disease \[[@CR2]\]. This objective was partially attained as has been shown in multiple studies \[[@CR3], [@CR4]\]. Further improvements towards the early identification of RA patients have been sought in several areas including the presence of autoantibodies. Two of them, RF and anti-CCP antibodies, have already an important role in the 2010 ACR/EULAR RA classification criteria. The presence of any of these antibodies at titers over the upper limit of normal (ULN) is scored as 2 points or as 3 points if \> 3 times the ULN. These scores represent a significant fraction of the 6 points required for RA classification. Other autoantibodies, including the anti-carbamylated protein antibodies (ACarPA), have been assessed, but none has significantly improved the classification obtained with RF and anti-CCP antibodies \[[@CR5]--[@CR7]\]. However, none of these evaluations has assessed the value of the concordant presence of the RA antibodies as a classifier. It is already known that the triple concordance is associated with extremely high specificity for RA, but analysis of its role in RA classification among EA patients has not been performed \[[@CR8]\]. Therefore, the possibility that the concordant presence of RA autoantibodies could improve RA classification seemed worth to explore. Accordingly, we analyzed the data of the 1057 patients from the two Spanish EA cohorts included in Regueiro et al. \[[@CR6]\] to assess the value of new criteria considering antibody concordance.

Methods {#Sec2}
=======

The patient information and the antibody determinations have already been reported \[[@CR6]\]. Briefly, EA patients from two prospective clinics in Madrid, PEARL \[[@CR9]\] and IdiPAZ \[[@CR10]\] recruited between July 2001 and December 2014 at PEARL and between January 1993 and December 2013 at IdiPAZ were studied. The entry criteria for the EA clinics were 2 or more swollen joints for less than a year and the absence of previous treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARD). The patients were classified at the end of the 2-year follow-up according to the 1987 American College of Rheumatology (ACR) classification criteria \[[@CR11]\]. This classification in RA and non-RA was used as the gold standard. The antibodies were determined in the sera from the first visit. The IgM-RF was assessed by nephelometry, whereas anti-CCP antibodies (ACPA) and anti-carbamylated protein antibodies (ACarPA) were determined by ELISA. The latter was a previously described home-made assay performed at Santiago de Compostela using in vitro carbamylated proteins from fetal calf serum as antigen \[[@CR12], [@CR13]\]. Briefly, we used FCS (F-7524, Sigma-Aldrich) at 4 mg/mL as a source of proteins for in-vitro carbamylation with 1 M KCNO, or with 1 M KCl as control, during 15 h at 37 °C. The efficiency and percentage of carbamylation were corroborated by HPLC in a Biochrom 30 amino-acid analyzer (Biochrom, UK). The ACarPA reactivity was assessed in duplicated diluted serum samples (50 μL at 1:50 dilution) incubated in separate Nunc MaxiSorp flat-bottom 96 well plates coated either with carbamylated or with native FCS (0.5 μg/well). IgG antibodies were detected using ALP-conjugated goat anti-human IgG (Jackson Immunoresearch Europe, UK). Reactivity to native FCS was subtracted from the reactivity to carbamylated FCS. A standard curve made with serial dilutions from a pool of positive sera was used to measure antibody titers in arbitrary units. The cut-off for positivity was set as the 98% specificity level obtained in 208 healthy controls.

The serological criteria according to the 2010 ACR/EULAR criteria were evaluated \[[@CR2]\]. They comprised three levels: negative, low positive and high positive based in RF or anti-CCP titers. Negative titers were below the upper limit of normal (ULN), whereas low and high positive levels were defined in relation with 3 times the ULN \[[@CR2]\]. In addition, the new criteria based on the concordance of the three autoantibodies were considered. All the levels were considered as categorical variables and only main effects were ascertained. The OR and their 95% confidence intervals were obtained from the logistic regression models. In addition, the model fit was assessed with the Nagelkerke *R*^2^, and the Akaike's Information Criterion (AIC). The Nagelkerke *R*^2^ estimates the predictive power of the model as a proportional reduction in error variance. The AIC estimates the relative amount of information lost by any model. Therefore, the R^2^ measures increase with the predictive power of the model, whereas the AIC reaches lower values for the best models. Differences in AIC \> 2 between two models are meaningful, whereas differences \> 10 are interpreted as indicating essentially no support for the poorer model \[[@CR14]\]. The impact of the different serological criteria on the overall classification (serological + non-serological criteria) was explored in the patients from PEARL, who featured all the required information. This exploration was done in two ways. The first consisted of changing the serological scores in the 2010 ACR/EULAR criteria. The second classified the patients with logistic regression that combined the non-serological and serological criteria applying cut-offs that were adjusted to obtain a constant sensitivity. The results of these classifications were expressed as specificity (true nonRA/observed nonRA patients), sensitivity (true RA/observed RA patients) and accuracy ((true nonRA + true RA)/all patients). The statistical tests were performed with R using the Jamovi application \[[@CR15], [@CR16]\].

Results {#Sec3}
=======

The 1057 EA patients were stratified according to the serological component of the 2010 ACR/EULAR classification \[[@CR2]\], or according to the presence of three, two, one, or none of the RA autoantibodies (Table [1](#Tab1){ref-type="table"}). Therefore, the 2010 serological criteria classified the EA patients in three levels, whereas the concordance criteria produced four levels. There were clear discordances between the two stratifications. For example, the 54 patients presenting only ACarPA were scored 0 in the 2010 serological criteria and 1 in the concordance score, or the 46 patients at level 3 in the 2010 serological criteria that only presented 1 antibody (1Ab). However, the general distribution of frequencies was strongly correlated between the two systems (Gamma = 0.986, *p* \< 10^−16^). Table 1Contingency table of the EA patients according to the 2010 serological criteria and the antibody concordance criteriaAntibody concordanceScores0Ab1Ab2Ab3Ab2010 criteria 30 (0) ^a^46 (11.7)170 (43.1)178 (45.2) 20 (0)75 (67.6)33 (29.7)3 (2.7) 0498 (90.2)54 (9.8)0 (0)0 (0)^a^Each cell of the table contains the number of EA patients and, between brackets, the percentage of the row total they represent

Analysis of the EA patient strata showed that the highest positive predictive values (PPV) were obtained with the concordance criteria (Table [2](#Tab2){ref-type="table"}), both in the top and the medium levels corresponding to the concordance of 3 (3Ab) and 2 (2Ab) antibodies, respectively. The 96.1% PPV obtained with the concordance for the 3 antibodies would be sufficient to classify the patients as having RA. It was also noteworthy that the PPV obtained with the 1Ab level of the concordance criteria was remarkably similar to the PPV of the 2-points score of the 2010 serological criteria. Table 2Classification of the EA patients according to serological criteria2010 ACR/EULAR ^a^ConcordanceScoreRANon-RAPPV ^b^LevelRANon-RAPPV33504488.8%3Ab174796.1%2476442.3%2Ab1673682.3%--------1Ab6810738.9%012942323.4%0Ab11738123.5%^a^The serological criteria defined in the 2010 ACR/EULAR RA classification criteria or by the concordance of autoantibodies^b^*PPV* positive predictive value

The OR obtained separately with the 2010 ACR/EULAR and with the concordance criteria added a clear perspective of the high predictive power of the concordance of the 3 antibodies (OR = 80.9) relative to the observed with the high antibody titers in the 2010 criteria (OR = 26.1). Furthermore, the logistic regression model incorporating both criteria showed a significant contribution to the RA classification of the two (Table [3](#Tab3){ref-type="table"}). The criterion with the largest weight was the concordance of the 3 antibodies. It was followed in decreasing order by the 3-points score, the concordance of 2 antibodies, the 2-points score and the presence of only 1 antibody. The two latter classifiers lacked a significant contribution. Therefore, we also tested the combined criteria after deleting the stratum corresponding to the presence of 1 antibody (Table [3](#Tab3){ref-type="table"}). Table 3Analysis of the relative weights of the serological criteria and their combinations2010 ACR/EULAR^a^Concordance2010 + Ccd.2010 + Ccd.'StratumOR (95% CI) ^b^OR (95% CI)OR (95% CI)OR (95% CI)326.1 (18.0--37.8)--7.5 (3.3--17.0)7.0 (4.0--12.2)22.4 (1.6--3.7)--1.7 (0.8--3.7) ^c^1.6 (1.0--2.6) ^c^3Ab--80.9 (37.0--177.1)11.4 (3.7--35.2)12.2 (4.9--30.2)2Ab--15.1 (10.0--22.9)2.8 (1.2--6.8)3.0 (1.7--5.3)1Ab--2.1 (1.4--3.0)0.9 (0.5--1.8) ^c^--^a^The serological criteria from the 2010 ACR/EULAR RA classification criteria, the concordance (Ccd.) of autoantibodies, and their combination without modification (2010 + Ccd.) and after deleting the 1Ab stratum (2010 + Ccd')^b^OR and their 95% confidence intervals^c^This stratum did not contribute significantly to RA classification

Once the contribution of the two types of criteria was demonstrated, the OR corresponding to the patients stratified simultaneously with the combined criteria was determined. The results were compared with the OR corresponding to the 2010 ACR/EULAR serological criteria (Fig. [1](#Fig1){ref-type="fig"}). The maximum OR (OR = 94.0, 95% CI = 40.7--217.2) was obtained with the patients that were simultaneously positive for the 3 antibodies and showed 3-points in the 2010 score. The patients with 3-points and 2 concordant antibodies followed (OR = 22.1, 95% CI = 13.5--36.0). This latter OR was slightly smaller than the corresponding to the 3-points score of the 2010 ACR/EULAR criteria. Therefore, only the group of patients combining the 3-points score and the concordance for the 3 antibodies required a higher weight than in the 2010 ACR/EULAR criteria. Fig. 1Odds ratio for RA classification corresponding to the EA patients stratified according to the combined 2010 ACR/EULAR and the concordance serological criteria

It was also relevant to assess the overall performance of the different serological criteria. This evaluation was done determining the R^2^ and AIC of each model. The R^2^ estimates the fraction of the variance that is accounted by the criteria, whereas the AIC is proportional to the information loss taking into consideration the complexity of the model. The two measures were concordant in all the comparisons (Table [4](#Tab4){ref-type="table"}). They showed that the performances of the 2010 ACR/EULAR serological criteria and the concordance criteria were almost identical (Table [4](#Tab4){ref-type="table"}). In contrast, the combination of the two types of serological criteria explained a higher fraction of the variance and showed a lower AIC than the separate criteria. The difference was highly favorable to the combined models relative to the separate criteria, as the change in AIC was \> 30 and a difference of 10 is already considered very convincing \[[@CR14]\]. However, there were no differences between the combined criteria including or excluding the patients that were only positive for 1 antibody. Table 4Overall fit of the models with different serological criteria for RA classificationModel fit2010 ACR/EULAR ^a^Concordance2010 + Ccdc.2010 + Ccdc.'*R*^2^0.4520.4540.4830.483AIC1033.31033.81001.8999.9^a^The serological criteria from the 2010 ACR/EULAR RA classification criteria, or based on the concordance of autoantibodies, and their combination without modification (2010 + Ccd.) and after deleting the 1Ab stratum (2010 + Ccd')

As a final test, we also compared the classification performance of criteria that included the non-serological component together with each of the serological criteria. This analysis was only possible with a fraction of the patients (537 patients), but the results followed the above described: modest improvements with the alternative models (Table [5](#Tab5){ref-type="table"}). The concordance criteria showed the same sensitivity than the 2010 ACR/EULAR criteria with a 2.7% increase in specificity, and the combined criteria brought a further increase of 1.1% in specificity together with a 1.8% improvement in sensitivity. These performance changes meant that 15 less patients were wrongly classified with the combined criteria than with the 2010 ACR/EULAR criteria of a total of 180 misclassified patients with the latter. As these results depend on the scores, we attributed to each level of autoantibodies, we also performed a comparison of the criteria without scores, directly from the logistic regression (Table [5](#Tab5){ref-type="table"}). This analysis was adjusted to obtain 80% sensitivity with all the criteria. The results were similar, showing the same rank of specificities and accuracies. The improvement in specificity with the combined criteria over the 2010 ACR/EULAR criteria was 3.1% in this comparison. Table 5Performance of the classification criteria for RA with different serological componentsSerological componentScores ^a^Logistic regression ^b^SpecificitySensitivityAccuracySpecificityAccuracy2010 ACR/EULAR72.678.875.873.777.1Concordance75.378.877.174.977.8Ccdc. +  201076.480.678.876.878.6^a^Scores were as in the 2010 ACR/EULAR criteria; or depending on the number of concordant antibodies as 5 for 3, 3 for 2, and 1 for 1 antibodies; or combining the two criteria as 5 for 3 or 2 antibodies with high titres, 3 for 3 or 2 antibodies with low titres, and 1 for 1 antibody irrespective of the titres^b^Classification was done with logistic regression including the non-serological and the serological criteria and adjusted to obtain 80% sensitivity

Discussion {#Sec4}
==========

Our results have suggested a way to improve the RA classification of EA patients by incorporating the concordant presence of 3 RA autoantibodies. This approach is supported by various analyses. First, the higher PPV of the concordance for 3 or 2 antibodies than of the current serological component of the 2010 ACR/EULAR criteria. Second, the independent contributions of the concordance of antibodies and of the 2010 serological criteria to prediction models that combined them. Third, the increase in fit to the data of the combined prediction models relative to the current serological criteria. Fourth, the exploratory analysis showing improved performance of the classification criteria that included a combined serological component. These analyses also lead to the realization that a sizeable set of EA patients, in whom the three antibodies are present, deserve direct classification as RA.

These improvements affect precision and discrimination of the classification among EA patients. They are aspects of the classification outside the main focus of recent research, which has been placed in reducing "the seronegative gap" \[[@CR17]\]. That is, in identifying autoantibodies that could serve as biomarkers in RA patients lacking RF and anti-CCP. However, the new RA autoantibodies that are best-established cover only a fraction of the seronegative gap \[[@CR5], [@CR13]\]. The gain in sensitivity afforded has not proved sufficient to compensate for the loss of specificity associated with increasing the number of alternative antibodies in EA patients \[[@CR5]--[@CR7]\]. Exactly this type of results led us and others to conclude that ACarPA did not contribute significantly to RA classification \[[@CR6], [@CR7]\]. Here, a change in perspective has shown the possibility of turning the concordance between RA antibodies into a source of useful information.

The insight leading us to consider antibody concordance as a potential classifier came from the demonstration of the high specificity of this phenotype \[[@CR8]\]. In effect, the concordant presence of RF, anti-CCP, and ACarPA showed specificities of 98--100% in a set of 12 case-control studies comparing: RA patients before disease development to healthy controls, and RA patients after clinical onset to healthy controls, or healthy first-degree relatives, or diseased controls \[[@CR8]\]. This high specificity, which was also observed in our EA patients (98.7%), led the authors to propose that triple antibody positivity could be used to identify individuals at risk of developing RA.

The most evident improvement that concordance of antibodies could provide is the direct classification of EA patients with 3 antibodies as RA. The PPV (96.1%) and OR (80.9) we have observed are sufficiently high as to propose this idea. The combination with the 2010 serological criteria was not necessary for this improvement, as it did not significantly modify classification at the top level.

In addition, the combined serological criteria permitted a more precise stratification of the RA prediction. For example, the high titres of RF or anti-CCP receive 3-points in the 2010 ACR/EULAR criteria, whereas with the combined criteria they were divided into three groups: those with 3 antibodies would be classified directly as RA (in the context of EA), the patients with 2 antibodies would remain in the 3-point level and the patients without concordant antibodies would receive a lower score. This detailed prediction led to the improvements reflected in the measures of model fit. Translating the increase in precision into practical benefit would require integration of the serological scoring with other clinical variables. According to the data obtained here, the serological scores in the future classification criteria will expand a larger range than currently. Predictably, they will include a top-level equivalent to RA classification provided that other criteria for EA are fulfilled and three or four lower scores. As an initial exploration, we set a four-level score for the serological component that increased its weight. It resulted in better performance of the classification than the obtained with the 2010 ACR/EULAR criteria. The same happened when the relative weights of each level were obtained from the logistic regression. A more definitive scoring system will require adjusting together the scores of the serological and non-serological components for optimal performance. Additional steps could be an assessment of the criteria by experts, as done with the 2010 ACR/EULAR criteria, and validation in independent EA patients including patients with any joint swelling, in place of the two swollen joints required in our EA cohorts.

We restricted this study to explore the potential benefit of concordance between RF, ACPA, and ACarPA because of its novelty and the need to decide if ACarPA could have any role in the classification of RA patients. However, there is strong evidence indicating that ACPA has more predictive value than RF (a feature also observed in our EA patients) and it could be possible to improve classification by differentiating between them. Also, the concordant presence of RF and anti-CCP could be used to improve classification without the need for new antibody determinations to the clinic. The PPV of the two-antibodies concordance in our patients was 93.1% and the OR = 43.9, which are higher values than those obtained with the 2010 serological criteria. These approaches based on the concordance of RF and anti-CCP or in differentiated scores for RF and anti-CCP will improve classification to a lesser degree, but do not require new antibody determinations beyond the widely available in the clinic. Finally, it is possible that other autoantibodies, different from the three considered here, could produce improvements in RA classification \[[@CR5], [@CR17]\].

Conclusions {#Sec5}
===========

Our results have shown the possibility of improving the discrimination and precision of the serological component in the RA classification of EA patients. Provided that our results are replicated, and extended to patients with one swollen joint, the top-level corresponding to the presence of the 3 antibodies will be sufficient for RA classification in the EA context. This step by itself could increase the number of patients receiving appropriate classification with a low fraction of false positives. However, the full advantage of the predictive power of antibody concordance will require modification of the weights given to each stratum of RA patients in the whole classification criteria.
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